The purpose of the NovoSeven trial is to evaluate the safety and efficacy of early administration of NovoSeven (recombinant factor VIIa) in reducing the frequency of hematoma growth and improving clinical outcome in acute intracerebral hemorrhage.

Eligible Participants are patients who have had a CT scan performed within 3 hours of stroke and who can be treated with factor VIIa within 60 minutes of the baseline CT.